
    
      -  Using block randomization, subjects of Low or intermediate (INT)-1 patients will be
           equally allocated to the following two types of regimens.

             1. Group A: azacitidine 75mg/m^2 subcutaneously for 7 days every 28 days + best
                supportive care

             2. Group B: azacitidine 75mg/m^2 subcutaneously for 5 days every 28 days + best
                supportive care

        -  The study drug, azacitidine, is provided free of charge by Celgene until disease
           progression or relapse after response, or intolerable toxicity occurs in clinical study
           subject, or informed consent is withdrawn.

        -  No crossover between arms is allowed.

        -  Dose escalation in this study is not allowed; on the contrary, dose reduction or dose
           delay is possible based on adverse events and hematologic recovery.
    
  